title: Safety and efficacy of aprepitant for chemotherapy-induced nausea and vomiting in pediatric patients: a prospective, observational study.
abstract: Pediatric patients between the ages of 12 months and 17 years with a confirmed malignancy who were scheduled to receive aprepitant as part of triple therapy antiemetic prophylaxis for a cycle of moderately- or highly emetogenic chemotherapy were eligible for enrollment. Patients were evaluated for the incidence of nausea, episodes of emesis, interference with activities of daily living (ADLs), and appetite through utilization of a patient survey. Eleven patients were enrolled for a total of 20 patient encounters, mean age 9.55 ± 4.85 (range, 12 months-17 years). Aprepitant was well-tolerated and complete response (CR) rate was 38.9%.
authors.affiliation: Department of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, Tennessee.
authors.forename: Megan
authors.initials: M
authors.lastname: Bodge
authors.forename: Alexandra
authors.initials: A
authors.lastname: Shillingburg
authors.forename: Stephan
authors.initials: S
authors.lastname: Paul
authors.forename: Lisa
authors.initials: L
authors.lastname: Biondo
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D000932:Antiemetics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D000077608:Aprepitant; D001835:Body Weight; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D015994:Incidence; D009025:Morpholines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy; D017294:Ondansetron / Q000008:administration & dosage / Q000627:therapeutic use; D011446:Prospective Studies; D012074:Remission Induction; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control
chemical_list: D000932:Antiemetics; D000077608:Aprepitant; D003907:Dexamethasone; D009025:Morpholines; D017294:Ondansetron
keywords: antiemetic; aprepitant; children; nausea and vomiting; nutrition; supportive care